https://doi.org/10.5281/zenodo.15826866

NEXUS KNOWLEDGE PUBLICATION

https://nknpub.com/index.php/1

Computer Aided Drug Development

ISBN Number- 978-81-985724-6-2

Chapter- 2



QUALITY-BY-DESIGN (QBD) IN PHARMACEUTICAL DEVELOPMENT

MS. PRAKRITI DIWAN UPADHYAY
Associate professor
Danteshwari College of Pharmacy,
Borpadar, Jagdalpur, 494221
Email: diwanprakriti26071991@gmail.com

DR. RITESH KUMAR
Associate Professor
Sharda School of Pharmacy, Sharda University Agra,
Uttar Pradesh, India, Pin- 282007
Email: ritesh.kumar@agra.sharda.ac.in

DR. RESHU TIWARI
Assistant Professor
Faculty of Pharmacy, Integral University,
Lucknow (UP) 226022
Email: reshu328790302@gmail.com

VINAY SAGAR VERMA
Associate professor
Kamla Institute of Pharmacy, Shri Shankaracharya Professional University (Previously known as Faculty of Pharmaceutical Sciences, Shri Shankaracharya Technical Campus)
Pincode: 490020
Email: Vinaysagarverma@gmail.com

DR. FARAH DEEBA
Assistant Professor,
Sharda University, Plot no 32,34,
Knowledge Park-III, Greater Noida,
Ruhallapur, Uttar Pradesh 201310
Email: farah.deeba@sharda.ac.in

Published By – Nexus Knowledge Publication

(Imprint of AKT Multitask Consultancy)

Bilaspur, Chhattisgarh, India, 495006

www.aktmultitask.com

https://doi.org/10.5281/zenodo.15826866

Chapter II…

QUALITY-BY-DESIGN (QBD) IN PHARMACEUTICAL DEVELOPMENT

MS. PRAKRITI DIWAN UPADHYAY
Associate professor
Danteshwari College of Pharmacy, Borpadar, Jagdalpur, 494221
Email: diwanprakriti26071991@gmail.com

DR. RITESH KUMAR
Associate Professor
Sharda School of Pharmacy, Sharda University Agra,
Uttar Pradesh, India, Pin- 282007
Email: ritesh.kumar@agra.sharda.ac.in

DR. RESHU TIWARI
Assistant Professor
Faculty of Pharmacy, Integral University, Lucknow (UP) 226022
Email: reshu328790302@gmail.com

VINAY SAGAR VERMA
Associate professor
Kamla Institute of Pharmacy, Shri Shankaracharya Professional University (Previously known as Faculty of Pharmaceutical Sciences, Shri Shankaracharya Technical Campus)
Pincode: 490020
Email: Vinaysagarverma@gmail.com

DR. FARAH DEEBA
Assistant Professor,
Sharda University, Plot no 32,34, Knowledge Park-III, Greater Noida,
Ruhallapur, Uttar Pradesh 201310
Email: farah.deeba@sharda.ac.in

https://doi.org/10.5281/zenodo.15826866

2.1 INTRODUCTION TO QBD PRINCIPLES

A methodical, risk- and science-based approach to pharmaceutical development, Quality by Design (QbD) places an emphasis on incorporating quality into a product from the very beginning rather than depending just on end-product testing. To ensure constant quality and performance, the fundamental tenet of QbD is to have a complete understanding of both the product and the production process. Determining Critical Quality Attributes (CQAs), developing a Quality Target Product Profile (QTPP), and comprehending the connection between Critical Material Attributes (CMAs) and Critical Process Parameters (CPPs) are all part of it. QbD assists in identifying critical factors that affect product quality and guarantees their proper control through risk assessment and design of experiments (DoE). In addition to increasing product safety and effectiveness, this proactive strategy lowers variability, boosts process efficiency, supports regulatory compliance, and promotes continuous improvement over the course of the product lifecycle. Regulatory bodies like the FDA and ICH strongly support QbD, which makes it a crucial part of contemporary drug development [1].



Figure 1: QBD process

2.1.1. Historical Background and Evolution of QbD

A time before Quality-by-Design (QbD) was formally recognised as a component of pharmaceutical development, the idea had its origins in the larger fields of quality management

https://doi.org/10.5281/zenodo.15826866

and engineering. QbD has its roots in the engineering and manufacturing sectors of the mid-1900s, especially in the groundbreaking research of quality specialist Dr. Joseph M. Juran. Juran proposed that rather than being checked into a product at the end of production, quality should be "designed into" it from the start. Understanding client needs, establishing quality objectives, creating procedures to achieve those objectives, and gradually enhancing those procedures were all key components of his methodology.

The pharmaceutical business, which has historically been heavily regulated, used a Quality-by-Testing (QbT) approach for many years, with an emphasis on end-product testing to guarantee quality. This method frequently resulted in inefficiencies, inconsistency, and reactive problem-solving, even though it helped maintain high standards. It became clear that a more proactive, scientifically directed approach to guaranteeing quality was required as technology developed and pharmaceutical products got more complicated. It was because of this realisation that QbD concepts were formally included into pharmaceutical processes [2].

The U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) were among the regulatory bodies that started pushing for a change to QbD in the early 2000s. This shift was primarily brought about by worries about growing expenses, the complexity of pharmaceutical products, and the requirement for stronger production methods. With its "Pharmaceutical cGMPs for the 21st Century" effort, the FDA began focussing on a risk-and science-based approach to pharmaceutical research and manufacture in 2004. Designing for quality was a key component of this concept.

Important recommendations, including ICH Q8 (R2) on pharmaceutical development, ICH Q9 on quality risk management, and ICH Q10 on pharmaceutical quality systems, were released by the International Council for Harmonisation (ICH) to encourage the industry-wide implementation of QbD. With a focus on a thorough comprehension of product performance and production procedures, these principles described how businesses should methodically design their products and processes to guarantee predetermined quality.

QbD has developed over time from a regulatory requirement to a competitive advantage for pharmaceutical firms. QbD approaches are being used more and more in modern drug development to meet regulatory standards as well as to increase productivity, cut expenses, shorten time to market, and guarantee constant product quality. Nowadays, most people agree

https://doi.org/10.5281/zenodo.15826866

that QbD is crucial to creating strong, adaptable, and effective pharmaceutical operations that can satisfy the demands of a global market that is changing quickly.

As a result, QbD's historical evolution signifies a profound paradigm shift from a reactive to a proactive quality assurance mentality, which will continue to influence pharmaceutical R&D and manufacturing going forward.

2.1.2. Definition of QbD

To guarantee the steady delivery of high-quality products, a strategic strategy known as Quality by Design (QbD) is used in a number of industries, including manufacturing, product development, and medicines. It entails incorporating quality considerations into the whole product lifetime, from conception to production, in a methodical and proactive manner.

The goal of Quality by Design in the pharmaceutical industry is to improve the safety, effectiveness, and general quality of medications by streamlining the development, production, and control processes. It necessitates a thorough comprehension of the key process parameters (CPPs), which are the variables influencing the manufacturing process, and the product's critical quality attributes (CQAs), which are the quantifiable features that define its performance [3].

Finding and comprehending the connections between the product's CQAs and the CPPs that affect them is the fundamental tenet of Quality by Design. This information is obtained by combining statistical analysis, risk assessment, and scientific testing. Manufacturers can create a design space where the product can reliably satisfy the required quality requirements by carefully examining these linkages.

The range of CPPs that guarantee the product's CQAs fall within reasonable bounds is defined by the design space. It offers process optimisation flexibility while preserving the necessary quality standards. To guarantee consistency and predictability in product performance, producers can set up suitable process controls, monitoring strategies, and quality assurance systems within this design space.

Quality by Design implementation has a number of benefits. Manufacturers can lower variability, mitigate risks, and gain a better understanding of their operations thanks to it. Post-production issues are less likely when quality is incorporated into the product development and

manufacturing stages, allowing for the early identification and resolution of possible quality concerns. Moreover, QbD promotes continuous improvement by offering a structure for constant process innovation and optimisation.

2.1.3. Regulatory Perspectives (ICH Q8, Q9, Q10 Guidelines)

A pillar of contemporary pharmaceutical development is the regulatory viewpoint on Quality-by-Design (QbD), especially as it relates to the International Council for Harmonization's (ICH) recommendations. The recommendations offer a formal framework for incorporating QbD principles into pharmaceutical manufacturing, particularly ICH Q8, ICH Q9, and ICH Q10. These recommendations stress the necessity of a more methodical, scientifically informed approach to medication development and manufacturing procedures, with an emphasis on guaranteeing the constant quality of pharmaceutical products from the start [4].

ICH Q8: Pharmaceutical Development

The 2009 introduction of ICH Q8, "Pharmaceutical Development," a ground-breaking guideline, fundamentally changed the way that drug development is approached. The crucial significance of incorporating quality into a pharmacological product from the outset of its development cycle was publicly acknowledged by this guideline. It provided a paradigm that highlighted the connection between a pharmacological product's critical quality attributes (CQAs) and the critical process parameters (CPPs) that influence them. Pharmaceutical developers should make sure that product quality is ingrained in the design process rather than being left to chance by comprehending these relationships.

The recommendation promotes a thorough comprehension of the relationship between process variables and product attributes. It emphasises how crucial it is to base judgements made during the development process on science. By incorporating science and data-driven analysis into the core of product and process design, this strategy goes beyond conventional drug development techniques, which frequently placed more emphasis on fulfilling end-product specifications. Early detection of possible problems during the development stage is intended to guarantee the product's quality right away.

A fundamental idea presented in ICH Q8 is the "design space." This phrase describes the specified range of process parameters that can be used to create a product in order to achieve

the desired quality attributes. As long as the final product stays within the permissible range, the design space concept allows producers to modify process parameters without departing from regulatory compliance. This adaptability lowers costs and time to market by streamlining the development process and optimising manufacturing.

Additionally, in order to preserve product quality, ICH Q8 promotes the creation of an all-encompassing control approach that incorporates multiple components. To guarantee consistency and conformity to the intended product quality, this control method makes use of end-product testing, in-process controls, and carefully chosen raw materials. The goal of the control plan is to preserve the quality of the finished product by continuously monitoring and modifying the production process to ensure that any deviations are quickly found and fixed.

All things considered, the QbD methodology described in ICH Q8 moves the emphasis away from conventional end-product testing and towards a more comprehensive and proactive strategy. Improved product quality, less variability, and more effective and optimised manufacturing processes are made possible by this guideline, which places a strong emphasis on the design and comprehension of crucial quality attributes and process factors early in the development cycle. This method assists pharmaceutical companies in producing high-quality products that continuously satisfy regulatory requirements over the course of their lifecycle.

ICH Q9: Quality Risk Management

In order to supplement the principles of Quality by Design (QbD), ICH Q9, "Quality Risk Management," was created in 2005. It offers a structured framework for evaluating and managing risks at every stage of the pharmaceutical development process. Regardless of whether the risks originate from raw materials, process stages, or environmental variables, this guideline emphasises the significance of recognising and comprehending any risks that could impact product quality. ICH Q9 guarantees that quality is included into the product from the beginning and maintained throughout its lifecycle by proactively addressing these risks.

Risk assessment, which highlights the necessity of assessing hazards at different phases of development, is one of the main tenets of ICH Q9. This includes identifying risks early on that could affect the quality of the final product, like raw material selection or process condition variability. Pharmaceutical businesses can identify possible risks and take action to mitigate them before they have an impact on the finished product by carrying out comprehensive risk

assessments. Instead than responding to difficulties after they arise, the objective is to foresee and prevent problems that could jeopardise quality.

In order to reduce the impact of hazards that have been recognised, the guideline also encourages the adoption of risk control techniques. These tactics could include mitigation plans and backup plans to deal with risks should they arise, as well as preventive efforts to try to remove or lessen hazards before they appear. The emphasis is on creating thorough plans that outline precise steps to successfully control risks during the development and manufacturing phases, guaranteeing that the final product continuously satisfies quality standards [5].

Risk communication, which emphasises the significance of disseminating risk-related information to all parties engaged in the drug development process, is another crucial component of ICH Q9. From development teams to regulatory agencies, effective communication guarantees that all parties are aware of the risks and in agreement when making decisions based on risk assessment. This cooperative strategy helps guarantee that everyone is working towards the same goals and has a common understanding of how risks are being handled. It also promotes a transparent culture.

ICH Q9 guarantees that decisions are supported by scientific data and in line with regulatory requirements by integrating these risk management concepts into the development and manufacturing processes. In addition to improving the overall quality assurance of pharmaceutical goods, this methodical approach to risk management makes the development process more effective and predictable. Pharmaceutical businesses can improve product safety and performance while lowering the possibility of production or regulatory problems by addressing possible risks early and consistently throughout the product lifecycle.

ICH Q10: Pharmaceutical Quality System

Introduced in 2008, ICH Q10, "Pharmaceutical Quality System," is a comprehensive guideline that aims to maintain an efficient quality management system across the course of a product's lifespan. In order to guarantee that pharmaceutical goods are regularly produced with the required quality, the guideline emphasises the necessity of incorporating the concepts of Quality by Design (QbD) and risk management into the quality system. The idea of continuous improvement, which views quality as a continuing process of monitoring, evaluating, and

optimising systems to adapt to changing scientific, technological, and regulatory advancements rather than as a one-time endeavour, is a fundamental component of ICH Q10.

The emphasis on continuous development is one of the main tenets of ICH Q10. This principle emphasises how crucial it is to maintain improving the pharmaceutical quality system in order to stay up with new scientific findings, technological developments, and modifications to regulatory requirements. Maintaining and enhancing product quality while adjusting to a changing environment is the goal, guaranteeing that pharmaceutical products continuously fulfil the necessary requirements over the course of their lifecycle. This strategy of continuous improvement entails a dedication to pinpointing areas that require improvement and putting the right adjustments into place to support product quality.

The Pharmaceutical Quality System (PQS) is further defined in the guideline as a fundamental component that guarantees constant quality throughout the whole product lifetime. The PQS is based on a strong framework that combines continuous evaluations, process control, and quality risk management. This system's goal is to assist pharmaceutical companies in adhering to current good manufacturing practices (cGMPs) and guaranteeing that quality criteria are continuously fulfilled throughout the production process. By assisting companies in tracking production process performance and identifying any threats to product quality, the PQS enables the implementation of proactive control measures.

The lifecycle approach to pharmaceutical research and production is another essential component of ICH Q10. This strategy highlights how crucial it is to guarantee product quality from the very beginning of product design to manufacturing, distribution, and post-market monitoring. Pharmaceutical companies can guarantee that quality is maintained throughout the whole product lifecycle by using a lifecycle approach. This includes the initial development phase as well as the post-market phase, where continuous monitoring and surveillance are crucial for spotting any new safety issues or areas that could use improvement.

Businesses can guarantee that the quality of their products stays constant over the course of their lifecycle by including the ICH Q10 principles into their overall pharmaceutical quality system. This strategy helps to improve patient satisfaction and regulatory compliance while also guaranteeing the long-term safety and effectiveness of pharmaceutical products. Pharmaceutical firms that use these strategies are better prepared to handle the demands of a dynamic market, increasing operational effectiveness and product quality overall [6].

The Regulatory Shift: From End-Product Testing to QbD

A significant change in regulatory thinking is shown by these three guidelines: ICH Q8, Q9, and Q10. A more proactive strategy that emphasises comprehending and managing the complete development process, from design to manufacturing, has supplanted the conventional end-product testing method. This change guarantees that quality is ingrained in the product from the start and is not only the outcome of extensive testing.

This regulatory framework facilitates:

- **Innovation and Flexibility:** Pharmaceutical companies can investigate more creative manufacturing techniques with the design space idea without sacrificing quality, giving them more freedom to satisfy patient demands.
- **Reduced Risk of Failure:** Businesses can detect possible risks early and take corrective action by integrating risk management and quality systems, which results in more reliable processes and products.
- **Regulatory Compliance:** These recommendations assist pharmaceutical firms in conforming to international regulatory standards, guaranteeing that they fulfil the prerequisites for market access and drug approval.

The pharmaceutical industry's adoption of QbD concepts is greatly aided by the regulatory viewpoints offered by ICH Q8, Q9, and Q10. They provide a methodical, scientifically based approach to drug development and production, guaranteeing that quality is incorporated into each stage and lowering the possibility of unsuccessful product launches. The pharmaceutical industry's approach to product development has changed as a result of these recommendations, becoming more thorough, proactive, and effective.

2.1.4 Key Elements of QbD (QTPP, CQA, CPP, CMA)

The methodical approach to pharmaceutical development known as Quality by Design (QbD) is centred on creating and designing procedures that guarantee predetermined quality throughout the product's lifecycle. The fundamental components of QbD serve as the cornerstone for building a strong system that guarantees the intended level of product quality is continuously achieved. The Quality Target Product Profile (QTPP), Critical Material

Attributes (CMA), Critical Process Parameters (CPP), and Critical Quality Attributes (CQA) are some of these essential components. Every one of these elements is essential to guaranteeing that the finished pharmaceutical product satisfies patient expectations as well as legal needs [7].

1. Quality Target Product Profile (QTPP)

A key idea in QbD, the QTPP outlines the optimal properties and performance standards for a pharmaceutical product. It serves as a guide for creating the formulation and production procedures and is created early in the product development process. The QTPP lists the essential qualities that the finished product needs to have in order to guarantee its efficacy, safety, and quality. Drug potency, dissolution rate, stability, bioavailability, and the intended pharmacokinetic profile are a few examples of these qualities. Patient demands, legal requirements, and scientific knowledge of the drug's therapeutic goal are all taken into account when developing the QTPP. Once established, the QTPP provides the basis for determining and comprehending the connection between the characteristics of the pharmaceutical product and the manufacturing process, which in turn directs the creation of the full product lifecycle.

2. Critical Quality Attributes (CQA)

The physical, chemical, biological, or microbiological characteristics of a pharmaceutical product that need to be managed to guarantee its efficacy and safety are known as critical quality attributes. Throughout the development and manufacturing stages, CQAs must be tracked and kept within reasonable bounds because they have a direct impact on the product's performance and quality. Tablet hardness, dissolution rate, impurity profile, sterility, and pH level are a few examples of these characteristics. The QbD process depends on the detection and management of CQAs. They are crucial for guaranteeing that the product achieves the desired therapeutic result and are established based on the QTPP. By keeping CQAs within the intended range, the production process reduces the amount of variation in the finished product. The more precisely CQAs are managed, the more probable it is that the final product will continuously fulfil the necessary quality criteria.

3. Critical Process Parameters (CPP)

The elements of the manufacturing process that have a direct impact on the final product's CQAs are known as critical process parameters. To guarantee that the final product satisfies the required quality criteria, these factors are meticulously managed throughout the development and manufacturing phases. Temperature, pressure, mixing speed, pH, and residence time in reactors or formulation equipment are a few examples of variables that can be included in CPPs. Changes in these factors may result in notable adjustments to the CQAs, thereby jeopardising the drug's efficacy, safety, or quality. A thorough grasp of the connections between process parameters and CQAs is built using the QbD technique. This knowledge makes it possible to pinpoint the most important variables that must be strictly regulated in order to produce the intended product attributes. Sometimes a design space is established that allows CPPs to vary within predetermined bounds without compromising the quality of the finished product.

4. Critical Material Attributes (CMA)

The characteristics of active pharmaceutical ingredients (APIs), excipients, and raw materials that may affect the ultimate quality of the product are referred to as critical material attributes. To make sure that the materials used in the drug manufacturing process satisfy the requirements for safety, efficacy, and quality, CMAs are recognised and managed. The flowability and compressibility of excipients utilised in tablet formulations, as well as the API's polymorphic form, moisture content, purity, and particle size distribution, are examples of these characteristics [8]. Designing reliable and repeatable manufacturing processes requires an understanding of how CMAs affect the quality of the finished product. Changes in the material's characteristics can have a big impact on the therapeutic product's performance and consistency. Manufacturers may make sure that the raw materials used in production have a beneficial impact on the overall quality of the finished product by carefully choosing and managing CMAs. The fundamental components of QbD are the QTPP, CQA, CPP, and CMA, which work together to create a framework for the design and management of pharmaceutical processes and products. Pharmaceutical developers can streamline their operations, reduce risks, and guarantee the reliable creation of high-quality pharmaceutical goods by concentrating on these crucial components. In addition to improving product quality, this all-

https://doi.org/10.5281/zenodo.15826866

encompassing strategy shortens development times, boosts regulatory compliance, and raises the possibility of clinical success.

2.1.5 Benefits of QbD in Pharmaceutical Development

Instead of testing for quality after production, Quality by Design (QbD) is a novel method to pharmaceutical development that focusses on incorporating quality into the product from the beginning. It combines risk management with scientific ideas to guarantee that products are regularly produced to satisfy predetermined quality standards. Pharmaceutical firms can gain a number of important advantages by employing QbD, which enhances the effectiveness of the development process and the calibre of the finished product. Some of the main advantages of QbD in pharmaceutical development are listed below.

1. **Enhanced Product Quality and Consistency**

The emphasis on incorporating quality into the product from the outset is the main benefit of Quality by Design (QbD). This method guarantees that every batch satisfies the desired quality criteria while lowering variability. Manufacturers can better monitor and manage the manufacturing process by knowing the critical quality attributes (CQAs) and how they relate to the critical process parameters (CPPs). This ensures that every item sent to the market operates as intended and produces a consistent product with fewer problems. Patient safety and the medication's effectiveness are directly impacted by the final outcome, which is an overall improvement in product quality.

2. **Reduction in Development Time and Costs**

The proactive approach that QbD emphasises helps to cut down on the time and expenses involved in pharmaceutical development. Trial and error is reduced when the product and process are designed and the important parameters are clearly understood. This makes it possible for developers to identify possible problems more quickly and fix them early in the development process. Consequently, there are fewer expensive delays brought on by rework, extra testing, or formulation modifications. Because of this expedited procedure, safe, effective medications are brought to market more quickly and at a lower cost, which benefits both producers and customers [9].

https://doi.org/10.5281/zenodo.15826866

3. Improved Regulatory Compliance and Approval

QbD integrates quality control across the product lifecycle to make regulatory standards easier to comply with. The FDA and EMA, among other regulatory bodies, are beginning to acknowledge QbD principles as the industry standard for pharmaceuticals. Drug developers can show that their procedures and goods were created in a methodical and scientifically sound way by using QbD. In addition to increasing the chances of a successful approval, this results in a more effective regulatory filing procedure. Furthermore, by emphasising quality and consistency across the product lifecycle, producers lessen the likelihood of delays or product recalls brought on by non-compliance and are better prepared for inspections and audits.

4. Better Process Understanding and Flexibility

The profound comprehension of the medication research and manufacturing process that QbD offers is one of its main advantages. Pharmaceutical makers can learn more about how raw ingredients, process variables, and environmental influences affect the finished product by utilising technologies like Design of Experiments (DoE). With this knowledge, a "design space"—the range of circumstances under which the medicine can be manufactured without sacrificing quality—can be defined. Because of this production flexibility, businesses can modify their procedures to accommodate minor changes in raw materials or environmental factors without compromising the quality of the final product. This flexibility increases the manufacturing process's resilience and effectiveness.

5. Enhanced Risk Management

A key element of QbD is risk management. Developers can detect possible risks to product quality early on and put effective mitigation measures in place by doing systematic risk assessments throughout the product lifecycle. Controlling crucial elements that can impact the quality of the finished product, like raw materials and process parameters, is emphasised by QbD. Proactive risk management guarantees constant product performance, lowers the possibility of product failures, and eliminates the need for expensive remedial activities. Furthermore, QbD principles are in line with regulatory frameworks such as ICH Q9, guaranteeing that the pharmaceutical industry is equipped to manage possible hazards in a way that is grounded in science.

https://doi.org/10.5281/zenodo.15826866

2.1.6 Challenges in Implementing QbD

Despite its advantages, applying Quality by Design (QbD) in pharmaceutical development presents a number of difficulties. From the first research stage until commercial production, these difficulties occur at different phases of medication development. The following are some of the main obstacles that pharmaceutical companies encounter while putting QbD into practice [10]:

1. **Requirement for Comprehensive Knowledge and Expertise**

QbD necessitates a thorough comprehension of the process and the final outcome. This entails having a solid grasp of how equipment, raw materials, and processing variables impact the end product's quality. Pharmaceutical firms require qualified staff, including scientists, engineers, and regulatory specialists, who can use scientific principles to design and optimise the product and process in order to successfully adopt QbD. This frequently necessitates a large training and expert recruiting commitment. Furthermore, for businesses lacking adequate experience in these domains, the intricacy of comprehending the connections among critical quality attributes (CQAs), critical process parameters (CPPs), and critical material attributes (CMAs) can be intimidating.

2. **Upfront Investment in Time and Resources**

Because QbD is a proactive method, it requires significant time and resources to be allocated early in the development process in order to fully characterise the process and product. For instance, the Design of Experiments (DoE) technique necessitates extensive preparation, implementation, and analysis. As a result, more time is spent on research and development before the product is even prepared for commercial manufacturing or clinical trials. This initial cost can be a major barrier for many businesses, especially smaller ones with less resources. Furthermore, using QbD necessitates sophisticated technological tools for modelling, analysis, and simulation, all of which can be expensive.

3. **Resistance to Change and Organizational Culture**

Organisational resistance to change is one of the main obstacles to implementing QbD. Adopting a new paradigm like QbD necessitates a mental shift because many pharmaceutical businesses have been utilising traditional approaches for years. Adopting a proactive design

strategy that incorporates quality into every stage of development may be difficult for staff and management used to reactive methods, such as assessing the finished product for quality after manufacturing. The adoption of QbD may be slowed by organisational culture, particularly if leadership is not supportive or if the business is deeply rooted in historical procedures [11].

4. Regulatory Challenges and Uncertainty

Despite the growing adoption of QbD principles by regulatory bodies like the FDA and EMA, there is still significant ambiguity surrounding their application and interpretation. Clear documentation and a thorough scientific justification for all decisions taken during the development process are necessary for the application of QbD in regulatory submissions. However, there may be regional differences in the application of rules, and not all regulators may possess the same degree of knowledge or expertise with QbD. This may make it difficult to coordinate worldwide production processes and guarantee that the same standard of quality control is upheld across various regions.

5. Complexity of Data Management and Analysis

To apply QbD principles, a great deal of data must be gathered and analysed in order to comprehend the connections between the various elements that influence product quality. This information frequently originates from a variety of sources, including product testing, in-process controls, and raw materials. This massive amount of data can be difficult to manage and analyse, necessitating the use of analytical tools and reliable data management systems. Furthermore, a high level of computational power is required due to the intricacy of the investigation, which includes statistical modelling, risk assessments, and simulations. Pharmacies may have trouble guaranteeing data integration, consistency, and dependability, particularly if their data systems are antiquated or incompatible with QbD requirements.

6. Scaling Up from Laboratory to Commercial Production

The techniques can be difficult to scale up to commercial production, even though QbD works well in lab settings. From small-scale testing to large-scale manufacturing, variables like equipment constraints, scale-up unpredictability, and environmental effects can impact the product's quality and consistency. The design space and process parameters established in the early stages of development could not necessarily translate to production on a commercial

scale, necessitating additional modifications and verification. A difficult process, maintaining QbD principles throughout scale-up necessitates meticulous planning, ongoing oversight, and extra resources.

2.2 DESIGN OF EXPERIMENTS (DOE)

In a process or product development, the Design of Experiments (DoE) is a statistically structured method used to methodically examine the links between a number of input variables (factors) and output responses. DoE is a crucial part of Quality by Design (QbD) in the pharmaceutical and biopharmaceutical industries, assisting researchers in determining and comprehending how formulation elements, process variables, and their interactions impact a drug product's quality and performance. Compared to conventional trial-and-error techniques, DoE allows for more efficient exploration of the design space, identification of the most important variables, and process optimisation with fewer trials. Factorial designs, response surface methodology (RSM), and mixture designs are common DoE techniques that are appropriate for various kinds of research. DoE helps regulatory submissions by offering a concise, evidence-based defence of process control techniques, which not only improves product development by increasing robustness and reproducibility. All things considered, DoE promotes scientific comprehension and data-driven decision-making, which makes it a vital instrument in contemporary pharmaceutical research and development [12].



Figure 2: Design of Experiments

https://doi.org/10.5281/zenodo.15826866

2.2.1 Basics of Experimental Design

A systematic method for organising, carrying out, evaluating, and interpreting controlled tests or experiments is called the Design of Experiments (DoE). In order to determine ideal circumstances or create models that forecast a system's behaviour, the goal is to investigate the relationship between factors (independent variables) and outcomes (dependent variables). By methodically assessing the effects of several aspects at once, DoE is frequently utilised in the pharmaceutical development environment to streamline manufacturing procedures, enhance product quality, and quicken product development.

Here are the key principles and components that form the basis of experimental design:

Defining the Objective and Selection of Factors

Clearly defining the goal is the first stage in any experiment. This could entail improving manufacturing conditions, stabilising a drug formulation, or other aspects of pharmaceutical development. Choosing the variables that could affect the result is a critical next step after defining the goal. Temperature, pressure, component concentration, and processing time are examples of independent variables. The experiment is set up to investigate how changes in these independent variables impact the intended result (dependent variable) by comprehending the influence of each component. The range of influence of each factor is then determined by testing it at various levels (values), such as high, low, or moderate.

Designing the Experimental Structure

The structure of the experiment is constructed after the goal and contributing components have been established. The number of elements and levels being evaluated determines the type of experimental design. Although it can be resource-intensive, the Full Factorial Design provides a thorough understanding of factor interactions by evaluating every possible combination of factors and their levels. However, when dealing with several components, Fractional Factorial Design is more economical because it just tries a portion of the options. Response Surface Methodology (RSM), which uses sophisticated mathematical tools to identify ideal conditions, is utilised for more intricate interactions between components. Taguchi Methods, which emphasise robustness in industrial processes, are used to reduce variability and increase consistency [13].

https://doi.org/10.5281/zenodo.15826866

Randomization, Replication, and Control of Variables

To guarantee objective experimental outcomes, randomisation is crucial. By allocating experimental circumstances at random, it helps avoid systematic errors and improves the accuracy of the results by reflecting unpredictability in the real world. In order to verify the results and ensure reliability by controlling for random mistakes, replication entails conducting tests again under the same circumstances. In general, more replications provide findings that are more accurate and trustworthy. Furthermore, regulating variables such as raw material quality or ambient parameters (temperature, humidity) guarantees that the results are indeed the product of the components under examination and not outside effects**.**

Statistical Analysis and Interpreting Results

In order to ascertain whether the elements under investigation significantly affect the result, statistical analysis is crucial after data collection. Regression analysis, which measures the correlations between causes and responses, and analysis of variance (ANOVA), which assists in identifying significant differences between groups, are examples of common statistical tools. Confidence intervals are also calculated as part of the research to convey the degree of uncertainty surrounding the findings. Following data analysis, the results must be interpreted to determine whether the intended outcomes were attained and which elements, along with their interactions, have the biggest effects on the final result. Process optimisation is one of the next steps that are informed by this interpretation.

Optimizing the Process and Continuous Improvement

Optimization—finding the set of variables that yields the optimal result—is one of DoE's main objectives. In pharmaceutical development, for instance, it can entail determining the ideal production parameters for reliable product quality or the ideal circumstances for medication bioavailability. The results of early tests frequently inspire additional testing since the experimental process is iterative. These follow-up studies strengthen theories, enhance procedures, and guarantee that the final product or process is continuously improved. Better product quality, less variability, and more effective production processes are the results of this iterative cycle of testing, learning, and refining.

2.2.2 Types of DoE Techniques (Full Factorial, Fractional Factorial, Response Surface Methodology, etc.)

Techniques known as Design of Experiments (DoE) are employed to methodically organise and carry out tests in order to investigate the impact of various factors on a certain response. These strategies are essential for streamlining operations, enhancing product quality, and making effective use of resources across a range of sectors, including drug development. These are a few of the most popular DoE approaches; each has unique benefits based on the resources available, complexity, and scope.

Full Factorial Design

One of the most thorough methods in Design of Experiments (DoE) is full factorial design. In order to provide a comprehensive picture of the impacts of each element and their interactions, it entails testing every possible combination of values for every factor. For instance, a full factorial design would test all eight conceivable combinations of the factors (2^3) if three factors were taken into consideration, each with two levels (low and high). This approach's thorough analysis, which allows for a thorough understanding of both the main impacts and interactions between components, is one of its main advantages. Furthermore, by precisely identifying the components and their combinations that have the most effects on the result, a full factorial design offers correct insights. This approach is flexible and suitable for a wide range of experimental contexts because it does not rely on presumptions regarding factor interactions. Full factorial design does, however, have several drawbacks. Because the number of experimental runs grows exponentially with the number of components, it requires a lot of resources. For example, 16 runs are needed to test four factors with two levels each, which can be costly and time-consuming. Furthermore, the analysis of the data might grow complicated as the number of elements and levels rises, necessitating the use of advanced statistical tools and procedures in order to correctly interpret the results [14].

Fractional Factorial Design

Compared to full factorial design, fractional factorial design is more effective. It reduces the number of experimental runs needed by trying a subset (fraction) of the potential combinations of factors rather than all of them. Usually, a fraction of the total combinations—such as 1/2, 1/4, or 1/8—is selected. In comparison to full factorial designs, this method is less expensive

and time-consuming due to its ability to examine a smaller fraction of options, which is one of its many benefits. Furthermore, fractional factorial design is a desirable choice for situations requiring quick insights because it requires fewer experimental runs, allowing for faster findings. It works especially well for exploratory research, when the goal is to pinpoint the primary effects and a few significant interactions rather than carrying out a thorough study. Fractional factorial design does have certain drawbacks, though. The possibility of little interaction information is a significant disadvantage. Fractional factorial designs might not capture all factor interactions, particularly higher-order interactions, because fewer options are examined. Another problem is the possibility of aliasing, which occurs when certain components' effects are "aliased" or confused with those of other factors in the fractional design, making it challenging to distinguish between them. If not thoroughly controlled, this aliasing might hide the underlying correlations between causes and responses, resulting in incorrect conclusions.

Response Surface Methodology (RSM)

A group of statistical methods known as Response Surface Methodology (RSM) are used to model and examine issues where multiple variables affect the result. It is especially helpful when there is a suspicion that the relationship between factors and responses is nonlinear, which means that changes in one component may have different impacts at different levels. RSM uses second-order (quadratic) models to examine the interactions between variables and responses in order to determine the ideal conditions for a process or system. The Box-Behnken Design and the Central Composite Design (CCD) are essential elements of RSM. The Box-Behnken Design employs three levels for factors and does not require corner points, making it more effective for testing a large number of factors. In contrast, CCD adds "centre points" (where factors are at their median levels) and "axial points" (where one factor is set at extreme values) to estimate the curvature in the response.

RSM has a number of benefits. It makes it possible to optimise several aspects at once by examining their interactions, which aids in determining the ideal combination of factors. It works especially well at spotting interactions between variables and nonlinear effects that other approaches might overlook. Furthermore, RSM helps to optimise the ideal settings for the remaining variables by fine-tuning processes following wide optimisation using other techniques. RSM does, however, have several drawbacks. One significant drawback is the presumption that quadratic functions can be used to effectively model the relationship between

inputs and responses [15]. The results might not be trustworthy if this assumption is false. Additionally, RSM is sometimes more resource-intensive than fractional factorial designs because it necessitates more experimental runs, particularly when assessing many components.

Taguchi Methods

Genichi Taguchi created the Taguchi methods, which emphasise robust design with the goal of increasing consistency and reducing variation in production processes to improve product quality. The method uses a systematic approach to design tests that pinpoint the causes of variation in order to reduce the sensitivity of the process or product to uncontrollable influences, or "noise." The use of orthogonal arrays (OA), which enable evaluating numerous parameters at once with fewer experimental runs, is one of the fundamental ideas of Taguchi techniques. This method of investigating factor effects without a whole set of trials is resource-efficient. The Signal-to-Noise Ratio (SNR), which measures a process's robustness by contrasting the intended performance with fluctuations brought about by noise causes, is another crucial idea.

Taguchi techniques have a number of benefits. They are very resilient to variability, which means that even when external factors or the characteristics of the raw materials change, the final product or process stays the same. Furthermore, because fewer experimental runs are required, orthogonal arrays provide a more economical and efficient use of resources. Furthermore, the quality and consistency of products can be greatly enhanced by using Taguchi methods, which are quite successful in determining the variables that affect product variability. But there are some disadvantages as well. Taguchi approaches may overlook significant higher-order effects and have limitations in capturing intricate relationships between variables. Additionally, the approach is better suited for process optimisation than for determining the ideal circumstances for every element or investigating the entire spectrum of factor interactions.

Plackett-Burman Design

Finding the most significant elements among a vast number of variables is the main purpose of Plackett-Burman designs, which are employed in screening tests. When there are a lot of factors and running a complete factorial design is not feasible, this method is particularly helpful. By using a particular kind of fractional factorial technique and evaluating only a subset

of potential factor combinations, the Plackett-Burman design helps to minimise the number of experimental runs needed.

This design's effectiveness in screening is one of its key benefits. With fewer experimental runs, it makes it possible to identify the key effects and important variables from a wide pool of variables. This makes it perfect for large-scale screening, where the main goal is to rapidly identify the elements that have the most impact on the result so that follow-up tests may be more precisely targeted. This strategy does have several drawbacks, though. Plackett-Burman designs may not offer a thorough grasp of how various components affect the system when they cooperate because they are unable to identify interactions between factors. Furthermore, although this approach works well for screening, it is less appropriate for process optimisation since it ignores the interplay of variables, which is frequently essential for system optimisation or fine-tuning.

2.2.3 Importance of DoE in Pharmaceutical QbD

1. **Optimization of Formulation and Manufacturing Processes**

Ensuring the efficacy and consistency of a product is crucial in pharmaceutical development. In order to optimise the formulation and manufacturing processes under the Quality by Design (QbD) framework, Design of Experiments (DoE) is essential. Finding the ideal conditions that result in the required product quality is made possible by DoE, which methodically examines the relationships between a number of variables (such as component concentrations, process parameters, temperature, etc.) [16]. Pharmaceutical products are guaranteed to meet regulatory requirements and perform consistently throughout production batches thanks to this optimisation procedure, which also raises the product's overall quality. DoE offers a data-driven strategy for achieving stable formulations and dependable manufacturing procedures in the context of QbD, which is crucial for guaranteeing patient safety and product effectiveness.

2. **Identification of Critical Quality Attributes (CQAs)**

The physical, chemical, biological, or microbiological characteristics that must be kept under strict control to guarantee product quality are known as critical quality attributes, or CQAs. DoE plays a key role in recognising and comprehending CQAs in the context of QbD. DoE assists in identifying the elements—drug potency, dissolving rate, and stability—that have the

most effects on CQAs by testing various combinations of formulation ingredients and processing parameters. Since regulating CQAs is a fundamental tenet of QbD, this identification is essential to guaranteeing that the finished product continuously produces the desired therapeutic effect. Pharmaceutical firms may reduce variability and guarantee consistent product quality by using DoE to proactively identify the qualities that should be prioritised during development and manufacture.

3. Risk Management and Process Understanding

DoE aids in efficient risk management by offering insightful information on the connection between process factors and product performance. To reduce issues during production, it is crucial to comprehend any risks early in the development process, according to the QbD framework. DoE assists in locating possible causes of variability or failure by examining the ways in which various factors impact product outputs. This enables improved risk assessment and the application of control techniques. This thorough comprehension of process dynamics makes the manufacturing process more predictable and controllable by lowering the possibility of unforeseen deviations. It also helps determine how resilient the process is, making sure that the finished product stays within the necessary requirements even when raw materials or ambient conditions change.

4. Accelerated Development and Cost Efficiency

Costs are decreased and development times are accelerated when DoE is implemented inside the QbD paradigm. Because it frequently takes a lot of experiments to get the ideal formulation and process conditions, traditional trial-and-error methods of product development can be expensive and time-consuming. DoE, on the other hand, reduces the number of necessary trials by enabling more effective exploration of the design space through an organised approach to experimentation. DoE can rapidly determine the most important variables influencing product quality by testing several parameters and their interactions at the same time. This effectiveness helps to prevent expensive errors during manufacturing in addition to speeding up the development process. It also helps find cost-cutting and process-improvement strategies, such minimising the usage of pricey raw materials or improving manufacturing conditions.

5. Regulatory Compliance and Documentation

Regulatory agencies like the FDA and EMA stress the value of a strong and scientifically sound approach to drug development. DoE, a component of QbD, offers pharmaceutical businesses a systematic and data-driven approach to product development, assisting them in meeting these regulatory criteria. DoE makes certain that all of the variables affecting the product's quality are methodically managed and recorded. This paperwork is essential for regulatory submissions since it shows that the product development process is well understood and that it adheres to QbD standards. Businesses can produce the proof they need to demonstrate that their goods are regularly produced in accordance with predetermined quality standards by employing DoE. DoE also assists in comprehending the design space, which is essential for submitting a stronger regulatory application that can stand up to inspection and lessen the need for further adjustments.

2.2.4. DoE for Process Optimization and Formulation Development

In the pharmaceutical sector, Design of Experiments (DoE) is essential to the optimisation of formulations and manufacturing procedures. DoE is a methodical, data-driven strategy used in pharmaceutical development that helps producers and researchers pinpoint the critical elements affecting product quality, optimise those elements, and create reliable procedures. This helps to guarantee that the product consistently satisfies the required requirements while lowering waste and variability, which eventually improves efficiency and lowers costs [17].

1. Process Optimization

Process optimisation in pharmaceutical manufacturing is the process of fine-tuning several production process parameters to maximise efficiency and achieve the target product quality. The most ideal operating conditions can be found by methodically testing various process variables and their interactions, such as temperature, pressure, mixing speed, and processing time, using Design of Experiments (DoE). The qualities of the finished product, such as stability, hardness, and rate of dissolving, can be greatly impacted by variables such as granulation technique, excipient type, and compression force during the tablet production process. Manufacturers can determine the most important parameters that require control and evaluate how these aspects affect product qualities at the same time by employing DoE. A design space is created as a result of this method, which is a collection of operational

parameters that guarantee the process will consistently yield a product that satisfies the necessary quality standards. Improved scalability, which guarantees that processes optimised at a small scale can be dependably expanded to larger production volumes without noticeably degrading product quality, decreased variability, which helps pinpoint the precise circumstances under which a process remains stable and consistent, and cost reduction, which minimises the need for rework and batch failures, are some benefits of process optimisation using DoE.

2. Formulation Development

In order to create a pharmaceutical product that satisfies all necessary requirements for efficacy, stability, and safety, formulation development include choosing the best active pharmaceutical ingredients (APIs), excipients, and manufacturing procedure. By allowing researchers to methodically examine how multiple chemicals, their concentrations, and other formulation factors interact to affect the product's overall performance, Design of Experiments (DoE) is essential to formulation development. For example, the granulation process, filler type, and binder concentration can all have a big impact on the drug's stability, bioavailability, and patient compliance when creating a novel oral drug formulation. Formulation scientists may effectively examine the impacts of several constituent combinations and their concentrations at the same time by using DoE, which provides them with a greater understanding of how these aspects interact. Compared to conventional procedures, this methodology results in the production of optimised formulations with fewer experimental trials. Because DoE systematically identifies the factors influencing quality attributes, it allows scientists to test a wide range of formulation options in a relatively short amount of time. It also improves product consistency by reducing the number of experimental runs needed, which saves time, money, and resources while guaranteeing that the final product meets all intended quality and performance standards.

3. Integration of Process and Formulation Optimization

Integrating formulation development with process optimisation is a crucial component of pharmaceutical development. DoE makes a comprehensive approach possible by concurrently optimising formulation and process parameters, guaranteeing that the finished product is both highly manufactured and of high quality. The creation of a sustained-release formulation, for example, requires the optimisation of both the formulation's excipient selection and the

manufacturing process's compression force in order to produce the intended release profile. Pharmaceutical companies can avoid the issue of improving one component of the product while sacrificing another by employing DoE to optimise both elements simultaneously. All facets of the product development process are guaranteed to be in harmony with this integrated approach, producing a reliable and superior end product.

4. Continuous Improvement

The pharmaceutical business usually follows a mindset of continual improvement after DoE has been used to optimise a formulation and process. DoE makes it possible to continuously improve the process and final product over time. Manufacturers are able to make well-informed decisions regarding process modifications or new formulations by identifying any areas of possible improvement or risk through continuous testing and data analysis. Pharmaceutical producers can fulfil changing regulatory requirements, maintain high product quality, and adjust to new raw materials or technology by adopting DoE repeatedly. To sum up, DoE is a strong and crucial instrument for formulation development as well as process optimisation. Pharmaceutical items are guaranteed to be both high-quality and produced efficiently because to its methodical and data-driven approach, which makes it possible to identify the ideal product and process characteristics. Pharmaceutical businesses can also maintain an advantage in a market that is becoming more complex and competitive by using continuous improvement techniques and integrating process and formulation optimisation.

2.3 RISK ASSESSMENT AND MANAGEMENT

A crucial step in the pharmaceutical development process is risk assessment and management, which aims to detect, analyse, and reduce possible hazards that could affect a drug product's efficacy, safety, and quality. Finding possible risks at each stage of the product lifecycle—from drug research to manufacture to post-market surveillance—is part of this methodical approach. Using instruments like Failure Mode and Effects Analysis (FMEA), Hazard Analysis and Critical Control Points (HACCP), and risk matrices, risk assessment generally entails identifying hazards, assessing their possible impact, and estimating the likelihood that they may materialise. Following risk identification, risk management plans are created to reduce or manage the risks through process controls, corrective actions, and preventative measures [46]. In the framework of Quality by Design (QbD), risk management is essential to guaranteeing that Critical Process Parameters (CPPs) and Critical Quality Attributes (CQAs) are

https://doi.org/10.5281/zenodo.15826866

meticulously regulated to provide a reliable and superior product. In addition to ensuring regulatory compliance and patient safety, risk management aims to improve product reliability, save costs, and guarantee the robustness of the production process. Pharmaceutical businesses can reduce negative impacts, increase operational effectiveness, and promote trust in the performance and safety of their medicines by proactively managing risks.

2.3.1 Role of Risk Assessment in QbD

A key element of the Quality by Design (QbD) methodology used in pharmaceutical development and production is risk assessment. It functions as an organised approach to find, evaluate, and rank possible hazards that can compromise a product's performance, safety, and quality over the course of its lifecycle. Designing processes and products that are intrinsically robust is the main objective of QbD, and risk assessment is crucial to reaching this objective.

Risk assessment aids scientists and engineers in the early phases of product and process development by allowing them to methodically determine which variables, such as environmental influences, process parameters, or material qualities, have the biggest effects on Critical Quality qualities (CQAs). Development teams can focus their efforts on reducing the aspects that present the greatest risk to quality by knowing the potential risks connected to each component.

The Design Space, a collection of input variables and process conditions where the product continuously satisfies quality criteria, is defined with the use of risk assessment in QbD. It offers a scientific justification for choosing which variables can have reasonable freedom and which need strict control. This raises overall reliability, increases process efficiency, and lowers the chance of product failure [18].

Moreover, risk evaluation facilitates adherence to regulations. Pharmaceutical businesses are encouraged by regulatory bodies such as the FDA and EMA to implement QbD principles, which include formal risk management procedures. The case for flexible regulatory techniques, including real-time release testing and post-approval change management, is strengthened by a well-documented risk assessment, which shows a deep understanding of the product and process.

All things considered, risk assessment in QbD facilitates improved resource allocation, decision-making, and ongoing development. It guarantees that pharmaceuticals are created with an active emphasis on quality, which results in safer, more effective medications for patients as well as increased production efficiency and lower prices for businesses.

2.3.2 Common Risk Assessment Tools (FMEA, FTA, Ishikawa Diagrams)

To properly conduct risk assessments, the Quality by Design (QbD) framework makes use of a number of structured tools. The development of control techniques is guided by these instruments, which also assist in identifying possible sources of failure and evaluating their effect on product quality. Fault Tree Analysis (FTA), Failure Mode and Effects Analysis (FMEA), and Ishikawa Diagrams (Fishbone Diagrams) are some of the most used techniques.

Failure Mode and Effects Analysis (FMEA)

A methodical and proactive technique for locating possible failure spots in a process or product and evaluating the relative impact of these failures is called Failure Mode and Effects Analysis, or FMEA. By analysing three crucial factors—Severity, which gauges the seriousness of a failure's consequences; Occurrence, which calculates the probability that a failure will occur; and Detection, which evaluates the likelihood of detecting the failure before it affects the product quality—FMEA is an essential tool for risk prioritisation in the context of pharmaceutical Quality by Design (QbD). These three criteria are used to provide a score to each discovered failure mode, and the formula RPN = Severity × Occurrence × Detection is used to determine the Risk Priority Number (RPN). Failure modes that need quick attention and mitigation techniques are indicated by higher RPN values [19]. Granulation drying time, for example, may be identified by FMEA as a crucial parameter in tablet manufacturing; inadequate drying may result in moisture retention, which would compromise the stability and shelf life of the tablet. FMEA's main advantages are its capacity to efficiently prioritise risks, guaranteeing that attention is directed towards the most important problems, and its assistance in creating strong control methods to improve process reliability and product quality.

Fault Tree Analysis (FTA)

A top-down, deductive approach to failure analysis, fault tree analysis (FTA) starts with a significant unwanted occurrence, like a system failure or product defect, and methodically

works backward to identify all the underlying causes. FTA is very useful in pharmaceutical Quality by Design (QbD) for breaking down complex failures by graphically representing the chain of contributing elements in a tree diagram manner. A distinct hierarchical structure is created in this picture by placing the main event—the failure or defect—at the root and gradually branching out all possible contributory causes underneath it. For instance, an FTA can assist in identifying possible causes such as inappropriate granulation methods, the use of subpar or wrong excipients, or irregularities during the tablet compression stage if a pharmaceutical batch fails disintegration testing. One of FTA's main advantages is its capacity to offer a thorough and understandable graphical depiction of every potential failure pathway, which facilitates the comprehension and analysis of complicated issues. Furthermore, it helps quality teams and researchers better understand how different components combine to potentially contribute to the top event, which eventually results in better decision-making and focused risk control measures.

Ishikawa Diagrams

Ishikawa diagrams, sometimes referred to as cause-and-effect diagrams or fishbone diagrams, are helpful tools for determining, examining, and visualising every possible source of a given issue. The diagram looks like a fish's skeleton, with the primary issue or consequence at the "head" and the several types of causes branching off as the "bones." These categories, which offer a thorough framework for analysing the various influences on a given issue, frequently contain important elements like Methods, Materials, Machines, Manpower, Measurement, and Environment. An Ishikawa Diagram would enable the team to classify likely reasons under different sections in the pharmaceutical production scenario, for example, if there is variability in tablet hardness. The characteristics of the raw materials (under Materials), the tablet press settings (under Machines), the operator's expertise (under Manpower), and even the manufacturing environment (under Environment) could all be contributing factors. By emphasising several possible root causes, the diagram promotes a thorough and in-depth investigation and makes sure that no important component is missed. It is particularly helpful during brainstorming sessions in teams, where all potential contributing elements can be identified and assessed using the combined knowledge and insights of several stakeholders. Additionally, the visual depiction of the connections between different causes and the issue itself facilitates comprehension of intricate processes and identifies areas that need intervention, leading to more efficient approaches to problem-solving.

https://doi.org/10.5281/zenodo.15826866

2.3.3 Identifying Critical Quality Attributes (CQAs)

A key component of the Quality by Design (QbD) methodology is identifying Critical Quality Attributes (CQAs), which guarantees that the finished product satisfies all requirements for quality, safety, and efficacy. The physical, chemical, biological, or microbiological attributes of a product that need to be regulated within specified bounds in order to guarantee its quality are known as CQAs. These characteristics are essential for guaranteeing that the medication formulation works as planned in terms of safety, stability, and therapeutic efficacy. Finding CQAs requires a deep comprehension of the production process, the product's intended use, and the effects of many factors on product quality. Common CQAs for a tablet formulation, for example, could include characteristics like microbiological limits, content homogeneity, dissolution rate, and tablet hardness. To guarantee that the product has the intended therapeutic impact, each of these qualities is essential.

A thorough risk assessment and scientific understanding of the product's formulation and manufacturing process are frequently the first steps in identifying CQAs. Multidisciplinary teams of formulation scientists, process engineers, and quality control specialists must work together. Businesses can create reliable procedures that can generate reliable, high-quality goods by recognising the CQAs early in the development process. This preventative measure lessens the possibility that production-related quality problems will occur. Additionally, managing CQAs makes it possible to create a design space—a range of process parameters—where the CQAs continuously stay within predetermined bounds. This maximises production process efficiency and is necessary for regulatory compliance.

Furthermore, the idea of process control is closely related to the identification of CQAs. Following their identification, the CQAs serve as a reference for both the manufacturing process design and the choice of process parameters. For instance, when choosing excipients, modifying compression forces, or establishing drying conditions in the tablet production process, the CQAs pertaining to hardness and dissolution rates must be taken into account. Manufacturers can guarantee that the finished product stays constant and satisfies the required quality standards by keeping an eye on and managing these variables. To guarantee that product quality is maintained throughout the production process, the identification of CQAs also aids in the creation of efficient and effective control measures, such as in-process testing, process analytical technology (PAT), and real-time monitoring. Finding CQAs ultimately

guarantees that the product not only complies with legal standards but also meets consumer expectations and enhances patient safety [20].

2.3.4. Examples of Risk Management in Pharmaceutical Development

While navigating the difficulties of the development lifecycle, risk management is a crucial procedure in pharmaceutical development to guarantee that products fulfil safety, effectiveness, and quality standards. In order to ensure that the finished product is safe and effective, risk management aims to identify any risks early in the process, assess their impact, and put methods in place to reduce or mitigate those risks. Here are a few thorough illustrations of how risk management is used in the creation of pharmaceuticals:

1. **Drug Formulation and Stability Risks:** One of the most significant dangers in the early phases of pharmaceutical research is associated with the drug's composition. Making sure the formulation will remain stable over time and in a variety of environmental circumstances (such as temperature and humidity) is the risk here. For example, exposure to heat or moisture can cause some medications to deteriorate or lose their effectiveness. In this context, risk management entails identifying a product's shelf life using methods like stability studies and choosing the appropriate excipients and packaging materials to preserve product stability. Accelerated stability testing allows developers to forecast the drug's long-term behaviour, pinpoint the most important variables that could jeopardise stability, and implement risk-reduction techniques like formulation modifications or storage condition optimisation.
2. **Manufacturing Process Risks:** Another place where dangers are prevalent is in the manufacturing process. Defects in the finished product, such low bioavailability or erratic dissolving rates, might result from manufacturing process variability, such as uneven mixing, erroneous particle size, or inadequate compression force. Early detection of these possible causes of unpredictability is the main goal of risk management techniques in the manufacturing industry. For instance, manufacturers can determine critical process parameters (CPPs) that have a major impact on product quality by employing design of experiments (DoE) and process optimisation approaches. Additionally, risks related to batch-to-batch variability can be reduced by putting in place strong process control systems and quality assurance procedures. Using real-time analytical methods, like process analytical technology (PAT), to regularly

monitor important variables helps guarantee that the process stays within predetermined bounds and that any deviations are identified before they lead to quality flaws.

3. **Clinical Development and Patient Safety Risks:** Patient safety is the main risk in clinical trials. The possibility of unanticipated side effects or negative reactions can present serious dangers during clinical studies. In order to evaluate a drug's safety profile prior to human trials, comprehensive preclinical research must be carried out as part of effective risk management in this stage. Furthermore, risk-based monitoring techniques are employed to guarantee the safety and ethics of the clinical trials. For instance, researchers can reduce risks by modifying dose schedules or patient populations to enhance safety through adaptive clinical trial designs, which permit protocol revisions based on interim data. To spot any new adverse events early and take appropriate action, regular safety monitoring—such as pharmacovigilance activities—is crucial. Additionally, possible failure points in the clinical trial process, such as patient non-compliance or inaccurate dosing, can be identified and remedial measures can be implemented using risk assessment techniques like Failure Mode and Effects Analysis (FMEA).
4. **Regulatory Compliance Risks:** In pharmaceutical research, regulatory compliance is a crucial risk area since noncompliance can cause delays in medication approval or substantial expenses. Pharmaceutical businesses use strong regulatory tactics at every stage of development to reduce these risks. This involves making certain that the required paperwork, including the New Drug Application (NDA) and Investigational New Drug (IND) application, are produced in compliance with legal requirements. Conducting internal audits, making sure that all clinical and manufacturing procedures adhere to Good Manufacturing Practices (GMP) and Good Clinical Practices (GCP), and collaborating closely with regulatory bodies to guarantee that the medication satisfies the requirements for approval are additional examples of risk management strategies in this context. Additionally, businesses can detect possible compliance issues and put preventive measures in place by using risk assessment techniques like Fault Tree Analysis (FTA).
5. **Market and Commercialization Risks:** Risks associated with market acceptance and competition emerge once a medication is prepared for commercialisation. A drug's market share could be impacted, for instance, by competition from alternative medicines or generic versions. Changes in healthcare regulations, problems with

reimbursement, or modifications in patient preferences are further examples of market hazards. Before and throughout the product launch, comprehensive market research and competition analysis are conducted to comprehend the possible market landscape as part of risk management in this sector. Businesses can also use marketing strategy and pricing strategies to reduce these risks and guarantee effective product positioning. Additionally, firms can monitor the drug's performance in real-world settings through continuous post-marketing monitoring, which enables them to handle any difficulties that may occur after the drug's introduction.

2.4 COMPUTER APPLICATIONS IN QBD PROCESS DEVELOPMENT

Computer applications play a pivotal role in Quality by Design (QbD) process development by enabling a more systematic, data-driven, and efficient approach to pharmaceutical product and process design. Through the use of specialized software tools, such as Design of Experiments (DoE), multivariate data analysis (MVDA), and simulation platforms, researchers can identify and optimize Critical Quality Attributes (CQAs), Critical Process Parameters (CPPs), and the Design Space with greater precision and reduced experimental workload. These computer-aided tools allow for robust modeling and statistical analysis, enabling the prediction of process behavior under varying conditions and the identification of potential risks before they occur. Additionally, software applications help in visualizing complex data, monitoring process performance in real-time, and ensuring compliance with regulatory requirements. The integration of computer technologies in QbD facilitates informed decision-making, enhances product understanding, and ultimately leads to the development of high-quality pharmaceutical products with improved consistency, efficiency, and regulatory acceptance [21].

2.4.1 Simulation and Modeling Tools in QbD

Pharmaceutical scientists and engineers can forecast, comprehend, and optimise product and process performance without requiring a great deal of trial-and-error testing thanks to simulation and modelling tools, which are essential to Quality by Design (QbD). These technologies assist in creating reliable formulations and manufacturing techniques that reliably produce the required quality by representing real-world processes using mathematical models and computer-based simulations. Throughout the product lifecycle, QbD uses modelling and simulation to support decision-making, promote risk assessment, and develop a thorough understanding of the process.

https://doi.org/10.5281/zenodo.15826866

The capacity to rapidly and economically investigate a large variety of process conditions and formulation factors is one of the main benefits of simulation and modelling in QbD. Developers can model how changes in temperature, mixing speed, ingredient concentrations, or process time will affect critical quality attributes (CQAs) like stability, potency, or dissolution rate by building predictive models based on experimental data or first-principle knowledge. This saves time, money, and waste by enabling design space optimisation without physically producing every potential combination.

For instance, mixing operations in pharmaceutical manufacturing are frequently modelled using Computational Fluid Dynamics (CFD), which enables developers to forecast how various impeller types or tank shapes will affect blend homogeneity. The effects of particle size, flowability, and compression force on tablet hardness and friability can also be better understood by simulating tablet compression processes using Discrete Element Modelling (DEM). Mechanistic models can help create stable formulations and forecast chemical breakdown processes because they are based on fundamental chemical and physical laws [22].

Furthermore, QbD makes heavy use of statistical modelling approaches like Response Surface Methodology (RSM) and Multivariate Data Analysis (MVDA) to examine the connections between a number of input variables and the final product qualities. These statistical models assist in determining the critical material attributes (CMAs) and critical process parameters (CPPs) that need to be managed to guarantee constant product quality.

Tools for modelling and simulation help with risk management by enabling virtual risk assessments in addition to process comprehension. Proactively implementing risk mitigation methods is made possible by their assistance in visualising possible failure spots and assessing the likelihood and seriousness of hazards under various scenarios.

In general, the application of modelling and simulation tools in QbD improves regulatory compliance, shortens development schedules, increases predictability, fortifies process design, and produces pharmaceutical products that are more durable and dependable. In order to successfully and efficiently accomplish the objectives of QbD, their incorporation into pharmaceutical development is becoming more and more crucial as technology develops.

https://doi.org/10.5281/zenodo.15826866

2.4.2 Use of PAT (Process Analytical Technology) in QbD

In the pharmaceutical sector, Process Analytical Technology (PAT) is a crucial facilitator of Quality by Design (QbD) [23]. It describes a set of instruments, methods, and approaches used to measure vital performance and quality characteristics of raw and in-process materials in real time in order to develop, evaluate, and regulate manufacturing processes. Instead of depending only on end-product testing, PAT aims to guarantee that quality is ingrained throughout the product. Pharmaceutical firms can attain a greater degree of process understanding through the use of PAT, which will result in more reliable product quality, more productivity, and lower risk.

PAT tools provide continuous monitoring of critical quality attributes (CQAs) and critical process parameters (CPPs) during manufacturing in the context of QbD. Real-time information on variables including mix homogeneity, moisture content, particle size distribution, and chemical composition is provided by methods such automated in-line sensors, Raman spectroscopy, near-infrared spectroscopy (NIR), and particle size analysers. Because of the instant feedback and corrections made possible by this real-time information, processes are kept inside the specified design space, avoiding the manufacturing of non-conforming goods.

For instance, NIR spectroscopy can be used to track the consistency of medication distribution in the blend during the tablet manufacturing process. The batch quality can be preserved without the requirement for expensive rework or batch rejection by promptly adjusting the mixing time or speed if any divergence from the goal is found. Similar to this, PAT instruments can track the pH, dissolved oxygen, and nutrient contents of cell cultures used in the manufacturing of biopharmaceuticals, allowing for the best possible conditions for the highest possible product output and quality [24].

Real-time release testing (RTRT), in which products are released based on in-process data rather than comprehensive end-product testing, is also supported by the usage of PAT under QbD principles. This enhances overall product quality assurance while also quickening the production cycle. Additionally, the data produced by PAT systems helps to promote regulatory compliance and continuous improvement by fostering a deeper understanding of the process.

All things considered, PAT's incorporation into pharmaceutical QbD frameworks encourages a change from conventional quality control to a more proactive approach to quality assurance,

https://doi.org/10.5281/zenodo.15826866

which results in safer, more potent pharmaceutical goods and more productive production processes.

2.4.3 Software for Process Monitoring and Control

A key component of implementing Quality by Design (QbD) in pharmaceutical manufacturing is software for process monitoring and control. These specialised software solutions let manufacturers to tightly regulate critical process parameters (CPPs) and critical quality attributes (CQAs) by gathering, analysing, and interpreting vast amounts of process data in real time. Through constant manufacturing process monitoring, the software assists in identifying deviations, anticipating possible problems, and suggesting remedial measures before the quality of the final product is jeopardised. Improved product quality, process efficiency, and regulatory compliance result from this proactive strategy, which guarantees that pharmaceutical goods are made consistently within the designated design space [25].

Tools like multivariate data analysis (MVDA), statistical process control (SPC), real-time data capture, and predictive modelling are all integrated into sophisticated software platforms. Based on data-driven insights, these technologies enable firms to visualise trends, carry out root cause studies, and optimise operations. For instance, multivariate analysis is frequently performed using software programs such as SIMCA, Unscrambler, and JMP to decipher complex data sets using Process Analytical Technology (PAT) equipment. By automating data collecting, recipe administration, batch tracking, and decision-making procedures, Manufacturing Execution Systems (MES) and Distributed Control Systems (DCS) also serve vital roles in guaranteeing that all production stages meet predetermined quality requirements.

The ability to facilitate Real-Time Release Testing (RTRT) is one of the major benefits of employing software for process monitoring and control. Businesses can cut cycle times and manufacturing costs by releasing products based on in-process measurements rather than just end-product testing with the aid of software-driven analysis. Additionally, incorporating machine learning (ML) and artificial intelligence (AI) algorithms into contemporary software platforms improves predictive capabilities, allowing firms to anticipate equipment breakdowns, maximise resource use, and sustain continuous improvement initiatives.

Process monitoring and control software is an essential part of pharmaceutical QbD. It enables businesses to better understand processes, stay in compliance with regulations, improve

operational effectiveness, and eventually bring safer, more effective medications to market more quickly and reliably.

2.4.4 Role of Machine Learning and AI in QbD

1. **Enhancing Process Understanding**

Technologies like artificial intelligence (AI) and machine learning (ML) allow for a more thorough and in-depth comprehension of pharmaceutical operations. Knowing how critical process parameters (CPPs) and critical quality attributes (CQAs) relate to one another is essential to Quality by Design (QbD) [26]. Large and complicated datasets created during production or experimentation can be analysed using ML algorithms, which can reveal hidden trends, correlations, and patterns that conventional statistical techniques might overlook. Building more precise process models and forecasting how various factors impact product quality are made easier with this improved process understanding.

2. **Predictive Analytics and Risk Management**

Predictive analytics is made possible by AI and ML, which enables producers to anticipate possible deviations, process breakdowns, or product flaws before they materialise. A fundamental component of QbD is risk assessment, and by using past data to identify high-risk scenarios, machine learning models can enhance risk management. The entire risk profile of pharmaceutical research and manufacturing can be decreased by businesses taking proactive steps to control risks, optimise processes, and guarantee consistent product quality by anticipating problems early.

3. **Real-Time Process Monitoring and Control**

Real-time process monitoring gains intelligence and adaptability through the combination of ML and AI. In order to keep processes inside the specified design area, these technologies can dynamically modify control techniques based on ongoing learning from real-time process data. This feature is notably helpful when implementing Real-Time Release Testing (RTRT), which eliminates the need for extensive post-production testing and speeds up time-to-market by using AI-driven models to evaluate product quality instantly during manufacture.

4. Optimization of Formulation and Process Development

Supervised and unsupervised learning are two examples of machine learning approaches that may swiftly analyse many variables and situations to optimise formulation and process development. AI is able to simulate a wide range of scenarios, advise the optimum formulations, and indicate the best processing conditions, all without the need for traditional design of experiments (DoE) or trial-and-error procedures. In addition to reducing the number of testing runs and speeding up the development period, this also improves the resilience and performance of the final product.

5. Continuous Improvement and Adaptive Learning

The support of continuous improvement activities is one of the major ways that AI and ML contribute to QbD. Processes can develop and get better over time by using machine learning models that can be updated often as new production data becomes available. Maintaining a state of control throughout the product lifetime is a key component of QbD, and this adaptive learning capability makes sure that production processes remain optimised even as equipment, raw materials, or environmental circumstances change.

6. Support for Regulatory Compliance and Documentation

Under QbD frameworks, AI and ML techniques can help maintain thorough and correct documentation required for regulatory submissions. Process comprehension, control methods, and risk management initiatives are strongly demonstrated by automated data analysis, trend reporting, and deviation tracking. These technologies are essential for pharmaceutical manufacturing that is prepared for the future, as regulatory bodies such as the FDA are beginning to recognise the benefits of AI-based approaches in pharmaceutical development.

2.5 USE OF STATISTICAL SOFTWARE IN QBD

The use of statistical software in Quality by Design (QbD) is essential for designing, analyzing, and optimizing pharmaceutical processes with a high degree of precision and reliability. Statistical tools such as Design-Expert, JMP, Minitab, and SAS allow researchers to apply Design of Experiments (DoE), regression analysis, ANOVA, and multivariate statistical techniques to systematically explore the relationships between Critical Quality Attributes (CQAs), Critical Process Parameters (CPPs), and other influential variables. These tools enable

the identification of optimal process conditions, robust formulation designs, and predictive models that support the establishment of a design space [56]. By leveraging statistical software, researchers can effectively visualize data trends, assess variability, perform risk assessments, and make data-driven decisions throughout the development lifecycle. This enhances product quality, reduces time and cost in development, and ensures compliance with regulatory expectations, ultimately supporting a science-based and risk-managed approach in pharmaceutical manufacturing.

2.5.1 Importance of Statistical Analysis in QbD

1. **Establishing Strong Process Understanding:** Building a comprehensive understanding of manufacturing processes, which is the cornerstone of Quality by Design (QbD), requires statistical analysis. Pharmaceutical scientists can investigate the connections between critical process parameters (CPPs) and critical quality attributes (CQAs) by using statistical tools including regression analysis, analysis of variance (ANOVA), and multivariate analysis. These methods aid in determining the important factors that affect product quality and measuring how strongly these associations exist. The development team can confidently create methods that consistently produce products that fulfil predetermined quality criteria thanks to statistical proof.
2. **Design of Experiments (DoE) for Process Optimization:** A key component of QbD is the Statistical Design of Experiments (DoE), which is largely dependent on statistical concepts. DoE enables the simultaneous and organised variation of several process-affecting parameters, enabling the determination of ideal operating conditions. DoE employs statistical designs to methodically investigate a larger experimental area rather than altering one component at a time, which is laborious and ineffective. This method not only expedites development but also reveals how factors interact, resulting in a more robust and optimised process design that can function dependably in a variety of scenarios.
3. **Defining and Verifying the Design Space:** One of the most important regulatory requirements in QbD is establishing the "design space"—the range of allowed input variables that produce a high-quality output. Accurately modelling the design space requires statistical analysis. The impacts of variability within the design space can be predicted by developers using methods such as Monte Carlo simulations and response

surface methodology (RSM). A scientific justification for operational flexibility is provided by statistical tools, which aid in visualising the multidimensional space where all quality requirements are satisfied. Statistically validated design spaces are recognised by regulatory organisations like the FDA as proof of in-depth process knowledge.

4. **Monitoring Process Performance and Ensuring Control:** Statistical analysis is still essential for continuous process monitoring and control after process development and scale-up. To monitor whether the process is stable and within the design space throughout ordinary production, statistical process control (SPC) charts, capability analysis, and control limits are employed. By using statistical monitoring to identify patterns or changes early on, quality problems can be avoided before they happen. Furthermore, Real-Time Release Testing (RTRT) techniques, which verify product quality throughout manufacturing rather than through end-product testing, are supported by statistical data.
5. **Enabling Continuous Improvement and Lifecycle Management:** One of the main components of QbD is continuous improvement, which has a quantitative foundation thanks to statistical analysis. Businesses can find areas for improvement, lower unpredictability, and improve processes over time by consistently gathering and evaluating production and quality data. Predictive analytics, statistical trend analysis, and hypothesis testing make ensuring that modifications are supported by facts rather than conjecture. This dedication to data-driven decision-making enhances operational effectiveness, fortifies regulatory compliance, and preserves product quality throughout its lifecycle.

2.5.2 Common Statistical Tools and Software (Minitab, JMP, Design-Expert)

1. **Minitab**

The application of Quality by Design (QbD) in pharmaceutical manufacturing relies heavily on Minitab, a robust and adaptable statistical software tool. The program is frequently used for process optimisation, data analysis, and general quality enhancement. Throughout the production process, producers may make data-driven decisions thanks to Minitab's extensive statistical toolkit and user-friendly interface. In QbD, where comprehending and managing

https://doi.org/10.5281/zenodo.15826866

several factors is essential to guaranteeing product quality, it is especially well-suited for analysing complicated datasets.

Minitab's sophisticated skills in regression analysis, statistical process control (SPC), and design of experiments (DoE) are among its main advantages. Because it facilitates the construction of organised experiments to examine the connections between key process parameters (CPPs) and critical quality attributes (CQAs), DoE is a crucial part of QbD. Pharmaceutical manufacturers can discover the critical factors that have a major impact on product quality, ascertain the best operating conditions, and streamline procedures to get the required product attributes by employing Minitab's DoE tools. Higher levels of consistency in product quality, decreased variability, and more efficient production processes are the results of this.

Minitab's proficiency in multivariate analysis, in addition to its DoE skills, is crucial for evaluating the interplay between various elements that affect pharmaceutical production processes. A more thorough grasp of how several factors, either separately or in combination, affect product quality is made possible by multivariate analysis. The response surface methodology (RSM) in Minitab, for instance, can be used to determine the ideal combination of parameters that result in the highest possible level of product quality. In the pharmaceutical sector, where little adjustments to process parameters can result in large variations in product performance, this is especially helpful.

Additionally, Minitab provides strong statistical process control (SPC) tools, which are essential for tracking continuous industrial operations. Manufacturers may monitor process performance in real time and make sure the process maintains within predetermined quality standards by using SPC tools like control charts. Manufacturers may promptly identify deviations from standard operating conditions and take corrective action before faults arise by utilising Minitab to continually monitor processes. Minitab's capacity analysis tools also assist in assessing a process's performance in relation to its specifications, offering valuable information on areas that require improvement.

All things considered, Minitab is a crucial tool for pharmaceutical companies trying to successfully use QbD concepts. It is a tremendous help in determining important process parameters, streamlining manufacturing procedures, and guaranteeing constant and dependable product quality because of its capacity to manage big datasets and carry out intricate statistical

https://doi.org/10.5281/zenodo.15826866

analysis. Minitab is a complete system for improving pharmaceutical manufacturing processes and attaining regulatory compliance, with features including integrated DoE capabilities, real-time process monitoring, and statistical tools for process optimisation.

2. JMP

SAS created JMP, a powerful and interactive statistical program that is frequently used for data analysis, especially in the pharmaceutical sector. Its focus on using visualisation to make difficult statistical ideas more understandable is one of its main advantages. Pharmaceutical professionals may better comprehend their data and make defensible decisions based on clear visual representations thanks to JMP's user-friendly interface, which enables interactive data exploration. A vital tool for comprehending the intricate dynamics of pharmaceutical processes in Quality by Design (QbD), the ability to display data in a number of graphical formats makes it easy for users to spot trends, correlations, and anomalies.

JMP's extensive Design of Experiments (DoE) capabilities are a crucial component, as they are crucial in QbD for investigating parameter relationships and process optimisation. With the use of the program, users can methodically plan experiments to investigate the ways in which various factors interact and affect critical quality attributes (CQAs). This aids in discovering the optimal circumstances for product quality and the most crucial process parameters (PPs). By allowing users to investigate the simultaneous effects of several variables on product results, JMP's multivariate analytic capabilities further increase its usefulness. DoE and multivariate analysis in JMP work together to create reliable and effective pharmaceutical manufacturing procedures that guarantee the finished product satisfies all predetermined requirements.

JMP incorporates simulation and predictive modelling capabilities that are essential for QbD optimisation, in addition to its robust DoE and multivariate analysis tools. Before real production starts, users can fine-tune the manufacturing process by using predictive modelling to predict how changes in process parameters would affect product quality. By allowing users to simulate different scenarios and evaluate potential hazards, the software's risk analysis and modelling features further help process optimisation and risk management. JMP is an effective instrument for proactive quality control and continuous improvement in pharmaceutical production because of its predictive potential, which is particularly useful for foreseeing and addressing problems that may result in process deviations or product faults. In order to ensure

that the team as a whole is in agreement when making decisions based on data-driven insights, the sophisticated visualisation tools also assist in conveying these intricate findings to stakeholders.

3. **Design-Expert**

A crucial instrument in the field of Quality by Design (QbD), Design-Expert is specialised software created to expedite the Design of Experiments (DoE) procedure. It is especially made for planning, evaluating, and refining pharmaceutical production trials when several variables and reactions must be assessed at once. The main emphasis of the program is on reliable experimental designs, which guarantee that users can determine the best combinations of process parameters even in intricate production situations. Because of this, it is perfect for maximising process parameters (PPs) and critical quality attributes (CQAs) to reliably produce the intended level of product quality across batches.

Support for multiple DoE techniques, such as factorial designs, fractional factorial designs, and Response Surface Methodology (RSM), is one of Design-Expert's most notable characteristics. These methods are essential for determining the ideal circumstances for product quality and assessing the effects of various elements on the production process. For example, fractional factorial designs cut down on the number of experimental runs, increasing efficiency without sacrificing important insights, while factorial designs assist users in examining the impact of multiple factors at various levels. Particularly useful for examining the connections between various elements and how they affect responses is Response Surface Methodology (RSM), which offers comprehensive insights into how various process conditions affect CQAs. These techniques assist producers in optimising their operations to satisfy strict quality and regulatory requirements.

Additionally, Design-Expert provides strong sensitivity analysis and predictive modelling tools, both of which are essential for enhancing process consistency. Sensitivity analysis enables users to pinpoint the most important process variables, guaranteeing that changes in equipment or raw materials won't have a major impact on the end product's quality. This function helps identify which aspects need to be strictly regulated to preserve product quality, which is especially helpful when working in contexts where raw material quality may vary. Additionally, users may easily comprehend experimental results using the software's interactive visualisation capabilities, which convert complex statistical outputs into simple

https://doi.org/10.5281/zenodo.15826866

plots and graphs. This increases overall process efficiency and product consistency by facilitating users' ability to make well-informed decisions based on data-driven insights. With the help of these features, pharmaceutical companies can make sure they can sustain high production standards throughout time in addition to streamlining their operations.

REFERENCES

1. Chandershekar, A., Bhaskar, A., Mekkanti, M. R., & Rinku, M. (2020). A review on computer aided drug design (CAAD) and it's implications in drug discovery and development process. *International Journal of Health Care and Biological Sciences*, 27-33.
2. Chang, C. H., Hung, C. L., & Tang, C. Y. (2019, November). A review of deep learning in computer-aided drug design. In *2019 IEEE International conference on bioinformatics and biomedicine (BIBM)* (pp. 1856-1861). IEEE.
3. Chawla, R., Rani, V., Mishra, M., & Kumar, K. (2022). Computer simulation and modeling in pharmacokinetics and pharmacodynamics. In *Computer Aided Pharmaceutics and Drug Delivery: An Application Guide for Students and Researchers of Pharmaceutical Sciences* (pp. 217-254). Singapore: Springer Nature Singapore.
4. Chua, H. M., Moshawih, S., Goh, H. P., Ming, L. C., & Kifli, N. (2023). Insights into the computer-aided drug design and discovery based on anthraquinone scaffold for cancer treatment: A protocol for systematic review. *Plos one*, *18*(9), e0290948.
5. Chua, H. M., Moshawih, S., Kifli, N., Goh, H. P., & Ming, L. C. (2024). Insights into the computer-aided drug design and discovery based on anthraquinone scaffold for cancer treatment: A systematic review. *PloS one*, *19*(5), e0301396.
6. Comoglu, T., & Ozyilmaz, E. D. (2024). Pharmaceutical product development: a "quality by design"(QbD) approach. In *Dosage Forms, Formulation Developments and Regulations* (pp. 285-310). Academic Press.
7. Cui, W., Aouidate, A., Wang, S., Yu, Q., Li, Y., & Yuan, S. (2020). Discovering anti-cancer drugs via computational methods. *Frontiers in pharmacology*, *11*, 733.
8. Dalkas, G. A., Vlachakis, D., Tsagkrasoulis, D., Kastania, A., & Kossida, S. (2013). State-of-the-art technology in modern computer-aided drug design. *Briefings in bioinformatics*, *14*(6), 745-752.
9. Danthala, M., Gundeti, S., Kuruva, S. P., Puligundla, K. C., Adusumilli, P., Karnam, A. P., ... & Digumarti, R. R. (2017). Generic imatinib in chronic myeloid leukemia: survival of the cheapest. *Clinical Lymphoma Myeloma and Leukemia*, *17*(7), 457-462.

10. Das, P. S., Saha, P., & Abdul, A. P. (2017). A review on computer aided drug design in drug discovery. *World Journal of Pharmacy and Pharmaceutical Sciences*, *6*(7), 279-91.
11. Dave, V., Yadav, R. B., Yadav, S., Sharma, S., Sahu, R. K., & Ajayi, A. F. (2018). A critique of computer simulation software's used in pharmacokinetics and pharmacodynamics analysis. *Current clinical pharmacology*, *13*(4), 216-235.
12. de Sousa, N. F., Scotti, L., de Moura, É. P., dos Santos Maia, M., Rodrigues, G. C., de Medeiros, H. I. R., ... & Scotti, M. T. (2022). Computer aided drug design methodologies with natural products in the drug research against Alzheimer's Disease. *Current Neuropharmacology*, *20*(5), 857-885.
13. del Carmen Quintal Bojórquez, N., & Campos, M. R. (2023). Traditional and novel computer-aided drug design (CADD) approaches in the anticancer drug discovery process. *Current Cancer Drug Targets*, *23*(5), 333-345.
14. del Carmen Quintal Bojórquez, N., & Campos, M. R. (2023). Traditional and novel computer-aided drug design (CADD) approaches in the anticancer drug discovery process. *Current Cancer Drug Targets*, *23*(5), 333-345.
15. Djuris, J., Ibric, S., & Đurić, Z. (2024). Quality by design in the pharmaceutical development. In *Computer-aided applications in pharmaceutical technology* (pp. 1-21). Woodhead Publishing.
16. Duarte, Y., Márquez-Miranda, V., Miossec, M. J., & González-Nilo, F. (2019). Integration of target discovery, drug discovery and drug delivery: a review on computational strategies. *Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology*, *11*(4), e1554.
17. Ejiofor, I. I., & Ejiofor, M. E. (2022). Computer-Aided Drug Design. *Drug Repurposing: Molecular Aspects and Therapeutic Applications*, 347.
18. El Jurdi, N., Bankoff, M., Klein, A., & Saif, M. W. (2016). Perforation of the colon during imatinib mesylate (Gleevec) treatment in a patient with chronic myeloid leukemia (CML). *Cureus*, *8*(6).
19. Eskazan, A. E., Elverdi, T., Yalniz, F. F., Salihoglu, A., Ar, M. C., Ongoren Aydin, S., ... & Soysal, T. (2014). The efficacy of generic formulations of imatinib mesylate in the treatment of chronic myeloid leukemia. *Leukemia & Lymphoma*, *55*(12), 2935-2937.

20. Eskazan, A. E., Elverdi, T., Yalniz, F. F., Salihoglu, A., Ar, M. C., Ongoren Aydin, S., ... & Soysal, T. (2014). The efficacy of generic formulations of imatinib mesylate in the treatment of chronic myeloid leukemia. *Leukemia & Lymphoma*, *55*(12), 2935-2937.
21. Eskazan, A. E., Sadri, S., Keskin, D., Ayer, M., Kantarcioglu, B., Demirel, N., ... & Soysal, T. (2017). Outcomes of chronic myeloid leukemia patients with early molecular response at 3 and 6 months: a comparative analysis of generic imatinib and glivec. *Clinical Lymphoma Myeloma and Leukemia*, *17*(12), 804-811.
22. Faver, J. C., Ucisik, M. N., Yang, W., & Merz Jr, K. M. (2013). Computer-aided drug design: using numbers to your advantage. *ACS medicinal chemistry letters*, *4*(9), 812-814.
23. Gabrielsson, J., Andersson, K., Tobin, G., Ingvast-Larsson, C., & Jirstrand, M. (2014). Maxsim2—Real-time interactive simulations for computer-assisted teaching of pharmacokinetics and pharmacodynamics. *Computer methods and programs in biomedicine*, *113*(3), 815-829.
24. Garralda, E., Dienstmann, R., & Tabernero, J. (2017). Pharmacokinetic/pharmacodynamic modeling for drug development in oncology. *American Society of Clinical Oncology Educational Book*, *37*, 210-215.
25. Gemelli, M., Elli, E. M., Elena, C., Iurlo, A., Intermesoli, T., Maffioli, M., ... & Gambacorti-Passerini, C. (2020). Use of generic imatinib as first-line treatment in patients with chronic myeloid leukemia (CML): the GIMS (Glivec to Imatinib Switch) study. *Blood research*, *55*(3), 139-145.
26. Germani, M., Del Bene, F., Rocchetti, M., & Van Der Graaf, P. H. (2013). A4S: a user-friendly graphical tool for pharmacokinetic and pharmacodynamic (PK/PD) simulation. *Computer methods and programs in biomedicine*, *110*(2), 203-214.